SHR-1316
SHR-1316 is a pharmaceutical drug with 17 clinical trials. Currently 8 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 3 completed trials
Phase Distribution
Phase Distribution
6
Early Stage
10
Mid Stage
1
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
100.0%
3 of 3 finished
0.0%
0 ended early
8
trials recruiting
17
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases
Reverse Triple Negative Immune Resistant Breast Cancer
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC
Clinical Trials (17)
Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases
Reverse Triple Negative Immune Resistant Breast Cancer
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC
A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer
A Study of Chemoradiotherapy With SHR-1316 For Treatment of Locally Advanced Cervical Cancer
A Phase II Study of Triple-negative Breast Cancer Brain Metastases.
SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in ES-SCLC
Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02
A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors
A Trial to Evaluate Safety and Tolerability of SHR-1316 in Cancer Patients
Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)
Safety, Tolerability and Pharmacokinetics of the New Formulation SHR-1316 in Subjects With Advanced Tumors
A Trial of SHR-1316 Maintenance Therapy for Limited Stage Small Cell Lung Cancer
SHR-1316 in Combination With Chemotherapy in Patients With Esophageal Squamous Cell Cancer
Safety and Tolerability of SHR-1316 in Subjects With Advanced Tumors
All 17 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 17